Cargando…
Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation
Background: Tyrosine kinase inhibitors (TKIs) were the first drugs to use an intracellular signaling molecule as a therapeutic target. Unresponsiveness to TKIs limits therapeutic options, making allogeneic hematopoietic stem cell transplantation (HSCT) the only option leading to molecular remission....
Autores principales: | Carvalho, Franceli Ramos, Zuckermann, Joice, Paz, Alessandra, Fischer, Gustavo, Daudt, Liane Esteves, Rigoni, Lisandra Della Costa, Silla, Lúcia, Fogliatto, Laura, de Castro, Simone Martins, Pilger, Diogo André |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338279/ https://www.ncbi.nlm.nih.gov/pubmed/28286612 |
Ejemplares similares
-
Validation of the EBMT Risk Score for South Brazilian Patients
Submitted to Allogeneic Hematopoietic Stem Cell Transplantation
por: Pitombeira, Beatriz Stela, et al.
Publicado: (2013) -
Comment on: clinical impact of systematic nutritional care in adults submitted to allogeneic hematopoietic stem cell transplantation
por: Daudt, Liane Esteves
Publicado: (2012) -
Donor characteristics and hematopoietic stem cell transplantation outcome: experience of a single center in Southern Brazil
por: Paz, Alessandra, et al.
Publicado: (2018) -
Flow cytometry to identify bone-marrow relapse in blastic plasmacytoid dendritic cell neoplasm: a case report
por: Farias, Mariela Granero, et al.
Publicado: (2017) -
Immunosuppressive serum levels in allogeneic hematopoietic stem cell transplantation: pharmaceutical care contribution
por: CORRÊA, Paulo M., et al.
Publicado: (2016)